|
ALS2CR8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30449984148129E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35599999509617E-08 |
| Normal-vs-Stage2 |
3.74690000004563E-06 |
| Normal-vs-Stage3 |
2.59990029505275E-10 |
| Normal-vs-Stage4 |
1.53579999995213E-06 |
| Stage1-vs-Stage2 |
3.726800E-01 |
| Stage1-vs-Stage3 |
4.675800E-02 |
| Stage1-vs-Stage4 |
4.753600E-01 |
| Stage2-vs-Stage3 |
6.045600E-01 |
| Stage2-vs-Stage4 |
8.624000E-01 |
| Stage3-vs-Stage4 |
4.403000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.44020034681591E-10 |
| Normal-vs-AfricanAmerican |
1.456170E-01 |
| Normal-vs-Asian |
4.2132000000028E-05 |
| Caucasian-vs-AfricanAmerican |
1.085640E-02 |
| Caucasian-vs-Asian |
5.510200E-01 |
| AfricanAmerican-vs-Asian |
1.088770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.57530000050232E-08 |
| Normal-vs-Female |
3.16119996845998E-09 |
| Male-vs-Female |
2.832000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.12250000300551E-08 |
| Normal-vs-Age(41-60Yrs) |
1.39739999571731E-08 |
| Normal-vs-Age(61-80Yrs) |
6.27990000001688E-08 |
| Normal-vs-Age(81-100Yrs) |
1.076160E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.531000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.928000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.593030E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.395400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.657400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.108200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.605700E-02 |
| Classical-VS-Follicular |
1.204640E-01 |
| Classical-VS-Other |
3.975800E-01 |
| Classical-VS-Normal |
2.23470000282333E-08 |
| Tall-VS-Follicular |
3.839600E-01 |
| Tall-VS-Other |
8.812600E-01 |
| Tall-VS-Normal |
9.249599997041E-08 |
| Follicular-VS-Other |
7.872800E-01 |
| Follicular-VS-Normal |
2.82949999985682E-07 |
| Other-VS-Normal |
1.052370E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.51010004501018E-09 |
| Normal-vs-N1 |
3.243800E-04 |
| N0-vs-N1 |
2.328000E-01 |
|
|
